AveXis Archives -

Germany first in EU to get Novartis’ SMA gene therapy, costing almost 2m euros

https://pharmaphorum.com/news/novartis-eyes-smart-deal-for-sma-gene-therapy-in-uk/

Novartis offers reimbursement options as EU backs costly SMA therapy

https://pharmaphorum.com/news/novartis-reimbursement-options-as-eu-approves-ultra-pricey-sma-drug/

Novartis closes on EU approval for SMA gene therapy Zolgensma

https://pharmaphorum.com/news/novartis-closes-on-eu-approval-for-sma-gene-therapy-zolgensma/

AveXis rules out EU compassionate use of SMA gene therapy, says Biogen option is available

https://pharmaphorum.com/news/avexis-rules-out-eu-compassionate-use-of-sma-gene-therapy-zolgensma/

Gene Therapy Analytical Development

https://pharmaphorum.com/events/gene-therapy-analytical-development/

Weekly roundup: More questions for Novartis in Zolgensma scandal

https://pharmaphorum.com/views-and-analysis/weekly-roundup-more-questions-for-novartis-in-zolgensma-scandal/

PTC shares soar after SMA drug data impresses market

https://pharmaphorum.com/news/ptc-therapeutics-posts-solid-sma-data/

AveXis surges on promising gene therapy

https://pharmaphorum.com/news/avexis-surges-promising-gene-therapy/

Search